Das antithrombotische Potential des Gefäßendothels

• LITERATUR

• 1 Alhenc-Gelas F, Tsai S, Callahan K, Campbell W, Johnson A R. Stimulation of prostaglandin formation by vasoactive mediators in cultured human endothelial cells. Prostaglandins 1982; 24: 723-41.
• 2 Astrup T. Fibrinolysis in the organism. Blood 1956; 11: 781-806.
• 3 Ausprunk D H, Boudreau C L, Nelson D A. Proteoglykans in the microvasculature : I. Histochemical localisation in microvessels of the rabbit eye. Am J Pathol 1981; 103: 353.
• 4 Baenziger N L, Becherer P R, Majerus P W. Characterization of prostacyclin synthesis in cultured human arterial smooth muscle cells and skin fibroblasts. Cell 1979; 16: 967-74.
• 5 Baenziger N L, Fogerty F J, Mertz L F, Chernuta L F. Regulation of histaminemediated prostacyclin synthesis in cultured human vascular endothelial cells. Cell 1981; 24: 915-23.
• 6 Barzu T, Van Rijn J L M L, Petitou M, Molho P, Tobelem G, Caen J P. Endothelial binding sites for heparin. Biochem J 1986; 238: 847-54.
• 7 Bennet H S. Morphological aspects of extracellular polysaccharides. J Histochem Cytochem 1963; 11: 14.
• 8 Bergsdorf N, Nilsson T, Wallen P. An enzyme linked immunosorbent assay for determination of tissue plasminogen activator applied to patients with thromboembolic diseases. Thromb Haemost 1983; 50: 740-4.
• 9 Bevilacqua M P, Schleef R R, Gimbrone M A, Loskutoff D J. Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1. J Clin Invest 1986; 78: 587-91.
• 10 Binder B R, Spragg J, Austen K F. Purification and characterization of human vascular plasminogen activator derived from blood vessel perfusates. J Biol Chem 1979; 254: 1998-2003.
• 11 Binder B R, Spragg J. The effect of fibrin on the activity of purified human vascular plasminogen activator. In: Protides of the Biological Fluids. Peeters H. (Ed). Oxford: Pergamon Press; 1980: 391-4.
• 12 Blajchman M A, Senyi A F, Hirsh J, Surga Y, Buchanan M, Mustard M, Mustard J F. Shortening of the bleeding time in rabbits by hydrocortisone caused by inhibition of prostacyclin generation by the vessel wall. J Clin Invest 1979; 63: 1026-35.
• 13 Booyse F M, Osikowicz G, Scott F, Scheinbuks J. Isolation and characterization of a urokinase-type plasminogen activator (Mr = 54,000) from cultured human endothelial cells undistinguishable from urinary urokinase. J Biol Chem 1984; 259: 7196-205.
• 14 Boxer L A, Allen J M, Schmidt M, Yoder M, Baehner R L. Inhibition of polymorphonuclear leukocyte adherence by prostacyclin. J Lab Clin Med 1980; 95: 672-8.
• 15 Brommer E J P, Verheijen J H, Chang G T G, Rijken D C. Masking of fibrinolytic response to stimulation by an inhibitor of tissue-type plasminogen activator in plasma. Thromb Haemostas 1984; 52: 154-6.
• 16 Busch C, Ljungman C, Heldin C H, Wasteson A, Öbrink B. Surface properties of cultured endothelial cells. Haemostas 1973; 08: 142.
• 17 Busch C, Owen W G. Identification in vitro of an endothelial cell surface cofactor for antithrombin III: Parallel studies with isolated perfused rat hearts and microcarrier cultures of bovine endothelium. J Clin Invest 1982; 69: 726-9.
• 18 Busch C, Dawes J, Pepper D S, Wasteson A. Binding of platelet factor 4 to cultured human umbilical vein endothelial cells. Thromb Res 1980; 19: 129.
• 19 Busch P C. Sulfated glycosaminoglycans and vascular endothelial cells. In: Biology of Endothelial Cells. Jaffe E A. (Ed.). Boston: Martinus Nijhoff; 1984: 178-88.
• 20 Cariou R, Tobelem G, Soria C, Caen J. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N Engl J Med 1986; 314: 1193-4.
• 21 Carreras L O, Machin S J, Deman R, Defreyn G, Vermylen J, Spitz B, Van Assche A. Arterial thrombosis, intrauterine death and »Lupus« anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981; (January); 244-6.
• 22 Christensen L R. Streptococcal fibrinolysis: proteolytic reaction due to serum enzyme activated by streptococcal fibrinolysin. J Gen Physiol 1945; 28: 363-83.
• 23 Clarke R L, Orandi A, Cliff ton E E. Induction of fibrinolysis by venous obstruction. Angiology 1960; 11: 367-70.
• 24 Clopath P, Sinzinger H. Calcitonin increases porcine vascular prostacyclin formation. Prostaglandins 1980; 19: 1.
• 25 Colburn P, Bounassi V. Anti-clotting activity of endothelial cell cultures and heparan sulfate proteoglycans. Biochem Biophys Res Comm 1982; 104: 220.
• 26 Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980; 43: 77-89.
• 27 Colucci M, Paramo J A, Collen D. Generation in plasma of a fastacting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985; 75: 818-24.
• 28 Comp P C, Nixon R R, Esmon C T. Determination of functional levels of protein C, an antithrombotic protein, using thrombin-thrombomodulin complex. Blood 1984; 63: 15-21.
• 29 Cramer E B, Pologe L, Pawlowski N A, Cohn Z A, Scott W B. Leukotriene C promotes prostacyclin synthesis by human endothelial cells. Proc Natl Acad Sci 1983; 80: 4109-13.
• 30 Czervionke R L, Smith J B, Hoak J C, Fry G L, Haycraft D L. Use of a radioimmunoassay to study thrombin-induced release of PGI₂ from cultured endothelium. Thromb Res 1979; 14: 781-6.
• 31 Davidson J F, Lochhead M, McDonald G A, McNicol G P. Fibrinolytic enhancement by stanazolol: a double blind trial. Br J Haematol 1972; 22: 543-59.
• 32 Dusting G J, Moncada S, Vane J R. Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachidonic acid. Prostaglandins 1977; 13: 3-16.
• 33 Ehrman M L, Jaffe E A. Prostacyclin inhibits the development of ADP- and arachidonic-induced shape change and procoagulant activity. Prostaglandins 1980; 20: 1103-6.
• 34 Ellis E F, Oelz O, Roberts III L J, Payne N A, Sweetman B J, Nies A S, Oates J A. Coronary arterial smooth muscle contraction by a substance released from platelets: evidence that it is thromboxane A₂ . Science 1976; 193: 1135-7.
• 35 Ellis E F, Wright K F, Sherian PJones, Richardson D W, Ellis C K. Effect of oral aspirin on platelet aggregation and vascular prostacyclin (PGI₂) synthesis in humans and rabbits. J Cardiovasc Pharm 1980; 02: 387-97.
• 36 Engebretsen L F, Kierulf P, Brandtzaeg P. Extreme plasminogen activator inhibitor and endotoxin values in patients with meningococcal disease. Thromb Res 1986; 42: 713-6.
• 37 Erikson L A, Ginsberg M H, Loskutoff D J. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74: 1465-72.
• 38 Esmon C T, Owen W G. Identification of an endothelial cell cofactor for thrombincatalyzed activation of protein C. Proc Natl Adac Sci USA 1981; 78: 2249-52.
• 39 Esmon N L, Owen W G, Esmon C T. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 1982; 257: 859-64.
• 40 Esmon C T. Regulation of protein C activation by components of the endothelial cell surface. In: Vascular Endothelium in Hemostasis and Thrombosis. Gimbrone M A. (Ed). New York: Churchill Livingstone; 1986: 99-119.
• 41 Esmon N L, Carroll R C, Esmon C T. Thrombomodulin blocks the ability of thrombin to activate platelets. J Biol Chem 1983; 258: 12238-42.
• 42 Ferreira S H, Moncada S, Vane J R. Indomethacin and aspirin abolish prostaglandin release from the spleen. Nature New Biol 1971; 231: 237-9.
• 43 Flair D S, Marlar R A, Levin E G. Human endothelial cells synthesize protein S. Blood 1986; 67: 1168-71.
• 44 Fleisher L N, Tall A R, Witte L D, Miller R W, Cannon P J. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J Biol Chem 1982; 257: 6653-5.
• 45 Fujimoto T, O’Hara S, Hawiger J. Thrombin induced exposure and prostacyclin inhibition of the receptor for Factor VIII/ von Willebrand Factor on human platelets. J Clin Invest 1982; 69: 1212-22.
• 46 Gorman R R, Bunting S, Miller O V. Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins 1977; 13: 377-88.
• 47 Griffin J H, Evatt B, Zimmerman T S, Kleiss A J, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-3.
• 48 Gurewich V, Pannell R, Lovie S, Kelley P, Suddith R L, Greenlee R. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase: a study in vitro and in two chemical species. J Clin Invest 1984; 73: 1731-9.
• 49 Hajjar D P, Weksler B B. Metabolic activity of cholesteryl esters in aortic smooth muscle cells is altered by prostaglandins I₂ and E₂ . J Lipid Res 1983; 24: 1176-85.
• 50 Hamsten H, Wiman B, DeFaire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-63.
• 51 Hauert J, Bachmann F. Single chain urokinase (SCU-PA): proactivator of the contact phase-dependent fibrinolytic pathway. Fibrinolysis. 1986 suppll: 20.
• 52 Hawiger J, Parkinson S, Timmons S. Prostacyclin inhibits mobilization of fibrinogen binding sites on human ADP and thrombin treated platelets. Nature 1980; 195-7.
• 53 Holmer E, Lindahl U, Backström G, Thunberg L, Sandberg H, Söderström G, Andersson L O. Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin. Thromb Res 1980; 18: 861.
• 54 Hong S L. Effect of bradykinin and thrombin on prostacyclin synthesis in endothelial cells from calf and pig aorta and from human umbilical vein. Thromb Res 1980; 18: 787-95.
• 55 Huber K, Kirchheimer J, Binder B R. Characterization of a specific anti-human urokinase antibody. Development of a sensitive competition radioimmunoassay for urokinase antigen. J Lab Clin Med 1984; 103: 684-94.
• 56 Husain S S, Lipinski B, Gurewich V. Rapid purification of a high affinity plasminogen activator from human blood by specific adsorption on fibrin/Celite. Proc Natl Acad Sci USA 1981; 78: 4265-9.
• 57 Kaplan M H. Nature and role of the lytic factor in hemolytic streptococcal fibrinolysis. Proc Soc Exp Biol Med 1944; 57: 40-3.
• 58 Kirk J E. Anticoagulant activity of human arterial mucopolysaccharides. Nature 1959; 184: 369.
• 59 Korninger C, Speiser W, Wojta J, Binder B R. Sandwich ELISA for tPA antigen employing a monoclonal antibody. Thromb Res 1986; 41: 527-35.
• 60 Kruithof E K O, Tran-Thang C, Rasijn A, Bachman F. Demonstration of a fast acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-13.
• 61 Kulkarni P S, Roberts R, Needleman P. Paradoxical endogenous synthesis of a coronary dilating substance from arachidonate. Prostaglandins 1976; 12: 337-53.
• 62 Lechner K. A new type of coagulation inhibitor. Thromb Diath Haemorrh 1969; 21: 482-99.
• 63 Lechner K, Pabinger-Fasching I. Lupus anticoagulants and thrombosis. Haemostasis 1985; 15: 254-62.
• 64 Levin E G, Marzec U, Anderson J, Harker L A. Thrombin stimulates tissue plasminogen activator release from cultured endothelial cells. J Clin Invest 1984; 74: 1988.
• 65 Levin E G, Stern M D, Nawroth P P, Marlar R A, Fair D S, Fenton J W, Harker L A. Specificity of the thrombin-induced release of tissue plasminogen activator from cultured human endothelial cells. Thromb Haemost 1986; 56: 115.
• 66 Levine R I, Jaffe E A, Weksler B B. Tack-Goldman Nitroglycerin stimulates synthesis of prostacyclin by cultured human endothelial cells. J Clin Invest 1981; 67: 762-9.
• 67 Levine R I, Weksler B B, Marcus A J, Jaffe E A. Prostacyclin production by endothelial cells. In: Biology of Endothelial Cells. Jaffe E A. (Ed). Boston: Martinus Nijhoff 1984; 228-47.
• 68 Lindahl U, Roden L. Carbohydrate-pepti-de linkages in proteoglykans of animal, plant and bacterial origin. In: Glykoproteins. Gottschalk A. (Ed). Amsterdam: Elsevier; 1972: 491.
• 69 Lindahl U, Backström G, Malmström M. Biosynthesis of L-iduronic acid in heparin: epimerization of D-glucuronic acid on the polymer level. Biochem Biophys Res Commun 1972; 46: 985-91.
• 70 Lockhart M S, Taylor F B, Vigano D, Angelo S, DAngelo A. Neutralization of plasminogen activator inhibitor by activated protein C: the role of protein S and phospholipids. Fibrinolysis 1986; suppl 1: 38.
• 71 Loskutoff D J, Van Mourik J A, Erickson L A, Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci 1983; 80: 2956-60.
• 72 Loskutoff D J, Ny T, Sawdey M, Lawrence D. Fibrinolytic system of cultured endothelial cells: regulation by plasminogen activator inhibitor. J Cell Biochem 1986; 32: 273-80.
• 73 Luft J H. Fine structure of capillaries: the endocapillary layer. Anat Record 1965; 27: 436.
• 74 Mammen E F, Thomas W R, Seegers W H. Activation of purified prothrombin to autoprothrombin II. Thromb Diath Haemorrh 1960; 05: 218-49.
• 75 Mannucci P M, Rota L. Plasminogen activator response after DDAVP: a clinico pharmacological study. Thromb Res 1980; 20: 69-76.
• 76 Marciniak E, Murano G, Seegers W H. Inhibitor of blood clotting derived from prothrombin. Thromb Diath Haemorrh 1967; 18: 161-6.
• 77 Marcum J A, Rosenberg R D. Anticoagulantly active heparin-like molecules from vascular tissue. Biochemistry 1984; 23: 1730-7.
• 78 Marcus A J, Weksler B B, Jaffe E A, Broekman M J. Synthesis of prostacyclin from platelet derived endoperoxides by cultured human endothelial cells. J Clin Invest 1980; 66: 979-86.
• 79 Marlar R A, Kleiss A J, Griffin J H. Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood 1982; 59: 1067-72.
• 80 Marsh N, Gaffney P. Some observations on the release of extrinsic and intrinsic plasminogen activator during exercise in man. Haemostasis 1980; 09: 238-47.
• 81 Milstone H. Factor in normal blood which participates in streptococcal fibrinolysis. J Immunol 1941; 42: 109-16.
• 82 Moncada S, Gryglewski R, Bunting S, Vane J R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-5.
• 83 Moncada S, Herman A G, Higgs E A, Vane J R. Differential formation of prostacyclin (PGX or PGI₂) by layers of the arterial wall. An explanation of the antithrombotic properties of vascular endothelium. Thromb Res 1977; 11: 323-44.
• 84 Moore K L, Andreoli S P, Esmon N L, Esmon C T, Bang N U. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987; 79: 124-30.
• 85 Murata K, Makazawa K, Hamai A. Distribution of acidic glykosaminoglykans in the intima, media and adventitia of bovine aorta and their anticoagulant properties. Arteriosclerosis 1975; 21: 93.
• 86 Needleman P, Bronson S D, Wyche A, Sirakoff M, Nikolaou K L. Cardiac and renal prostaglandin I₂: biosynthesis and biological effects in isolated perfused rabbit tissues. J Clin Invest 1978; 61: 839-49.
• 87 Nordoy A, Svensson B, Wiebe D, Hoak J C. Lipoprotein and the inhibiting effect of human endothelial cells on platelet function. Circ Res 1978; 43: 527-34.
• 88 Owen W G, Esmon C T. Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 1981; 256: 5532-5.
• 89 Pandolfi M, Robertson B, Isacson S, Nilsson I M. Fibrinolytic activity of human veins in arms and legs. Thromb Diathes Haemorrh 1968; 20: 247.
• 90 Pannekoek H, Veerman H, Lambers H, Diergaarde P, Verweij C L, Van Zooneveld A J, Van Mourik J A. Endothelial plasminogen activator inhibitor (PAI): a new member of the serpin gene family. Embo J 1986; 10: 2539-44.
• 91 Paramo J A, Colucci M, Collen D, Van de Werf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 1985; 291: 573-4.
• 92 Parks W M, Hoak J C, Czervionke R L. Comparative effect of ibuprofen on endothelial and platelet prostaglandin synthesis. J Pharm Exp Ther 1981; 219: 415-9.
• 93 Preston F E, Whipps S, Jackson C A, French A J, Wyld P J, Stoddard C J. Inhibition of prostacyclin and platelet thromboxane A₂ after low-dose aspirin. N Engl J Med 1981; 304: 76-9.
• 94 Roden L. Structure and metabolism of connective tissue proteoglykans. In: The Biochemistry of Glykoproteins and Proteoglykans. Vol 5. Lennarz W J. (Ed). New York: Grune and Stratton; 1980
• 95 Rosenberg R D. Role of heparin and heparinlike molecules in thrombosis and atherosclerosis. Fed Proc 1985; 44: 404-9.
• 96 Roth G J, Stanford N, Majerus P W. Acétylation of prostaglandin synthetase by aspirin. Proc Natl Acad Sci USA 1975; 72: 3073-6.
• 97 Saba S R, Mason R G. Studies of an activity from endothelial cells that inhibits platelet aggregation, serotonin release and clot retraction. Thromb Res 1974; 05: 747-57.
• 98 Salem H, Broze G, Miletich J, Majerus P. Human coagulation factor Va is a cofactor for the activation of protein C. Proc Natl Acad Sci USA 1983; 80: 1584-8.
• 99 Salmon J A, Smith D R, Flower R J, Moncada S, Vane J R. Further studies on the enzymatic conversion of prostaglandin endoperoxide into prostacyclin by porcine aorta microsomes. Biochem Biophys Acta 1978; 523: 250-62.
• 100 Schafer A L, Cooper B, O’Hara D, Handin R I. Identification of platelet receptors for prostaglandin I₂ and D₂ . J Biol Chem 1979; 254: 2914-7.
• 101 Seegers W H, Novoa E, Henry R L, Hassouna H I. Relationship of “new” vitamin K-dependent protein C and “old” autoprothrombin II-A. Thromb Res 1976; 08: 543-52.
• 102 Siegl A M, Smith J B, Silver M J, Nicolaou K L, Ahern D. Selective binding site for H³-prostacyclin on platelets. J Clin Invest 1979; 63: 215-20.
• 103 Silbert J E. Biosynthesis of heparin -formation of a sulfated glycosaminoglycan with a microsomal preparation of mast cell tumors. J Biol Chem 1967; 242: 5146-52.
• 104 Simionescu N, Simionescu M, Palade G E. Differentiated microdomains on the luminal surface of the capillary endothelium. I. Preferential distribution of anionic sites. J Cell Biol 1981; 90: 605.
• 105 Sinzinger H, Feigl W, Silberbauer K. Prostacyclin generation in artherosclerotic arteries. Lancet 1979; II: 469.
• 106 Sobel G W, Mohler S R, Jones N W, Dowdy A B C, Guest M M. An activator of profibrinolysin extracted from urine. Am J Physiol 1952; 171: 768.
• 107 Speiser W, Anders E, Preissner K T, Wagner O, Müller-Berghaus G. Differences in coagulant and fibrinolytic activities of cultured human endothelial cells derived from omental tissue microvessels and umbilical veins. Blood 1987; 69: 964-7.
• 108 Speiser W, Bowry S, Anders E, Binder B R, Müller-Berghaus G. Method for the determination of fast acting plasminogen activator inhibitor capacity (PAI-cap) in plasma, platelets and endothelial cells. Thromb Res 1986; 44: 503-15.
• 109 Speiser W, Wojta J, Korninger C, Kirchheimer J, Zazgornik J, Binder B R. Enhanced fibrinolysis caused by tissue plasminogen activator release in hemodialysis. Kidney Int. 1987 (in press).
• 110 Speiser W, Langer W, Pschaick A, Selmayr E, Ibe B, Nowacki P E, Binder B R, Müller-Berghaus G. Activation of fibrinolysis by physical exercise in patients after myocardial infarction. Haemostasis 1986; 16: 59.
• 111 Speiser W, Anders E, Müller-Berghaus G. Cultured human omental tissue microvascular endothelial cells lyse fibrin clots in contrast to umbilical vein endothelial cells. (submitted).
• 112 Sprengers E D, Verheijen J H, Van Hinsbergh V W M, Emeis J J. Evidence for the presence of two different fibrinolytic inhibitors in human endothelial cell conditioned medium. Biochem Biophys Acta 1984; 801: 163-70.
• 113 Stenflo J. A new vitamin K-dependent protein: purification from bovine plasma and preliminary characterization. J Biol Chem 1976; 251: 355-63.
• 114 Stibbe J, Kluft C, Brommer E J P, Gomes M, De Jong D S, Nauta J. Enhanced fibrinolytic activity during cardiopulmonary bypass in open heart surgery in man is caused by extrinsic (tissue-type) plasminogen activator. Eur J Clin Invest 1984; 14: 375-82.
• 115 Svensson J, Hamberg M, Samuelsson B. On the formation and effects of thromboxan A₂ in human platelets. Acta Physiol Scand 1976; 98: 285-94.
• 116 Tateson J E, Moncada S, Vane J R. Effects or prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins 1978; 13: 389-97.
• 117 Teien A, Abildgaard U, Hook M. The anticoagulant effect of heparan sulfate and dermatan sulfate. Thromb Res 1976; 08: 859.
• 118 Tillett W S, Garner R L. Fibrinolytic activity of hemolytic streptococci. J Exp Med 1933; 58: 485-502.
• 119 Tollefsen D M, Petska C A, Monafo W J. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-7.
• 120 Tremoli E, Jaffe E A, Tack-Goldman K, Weksler B B. PGI₂ production by endothelial cells: effects of sera from normal and hyperlipidemic subjects. Arteriosclerosis 1985; 05: 178-83.
• 121 Van Hinsbergh V W M, Bertina R M, Van Wijngaarden A, Van Tilburg N H, Emeis J J, Haverkate F. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood 1985; 65: 444-51.
• 122 Van Mourik J A, Lawrence D A, Loskutoff D J. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem 1984; 259: 14914-21.
• 123 Wagner O F, Resch I, Binder B R. Influence of CnBr fibrinogen fragments on inhibition of tissue type plasminogen activator (t-PA) by purified endothelial type plasminogen activator inhibitor (PAI) derived from melanoma cell culture supernatnas. Fibrinolysis 1986; suppl 1: 27.
• 124 Walker F J. The regulation of activated protein C by a new protein: a possible function for bovine protein S. J Biol Chem 1908; 255: 5521-4.
• 125 Wasteson A, Gimelius B, Busch C, Westermark B, Heldin C H, Norling B. Effect of a platelet endoglykosidase on cell surface associated heparan sulfate of cultured human endothelial and glial cells. Thromb Res 1977; 11: 309.
• 126 Wasteson A, Höök M, Westermark B. Demonstration of a platelet enzyme, degrading heparan sulfate. FEBS Lett 1976; 64: 218.
• 127 Weiss H J, Turitto V T. Prostaglandin I₂ (PGI₂) inhibits platelet adhesion and thrombus formation on subendothelium. Blood 1979; 53: 244-50.
• 128 Weksler B B, Marcus A J, Jaffe E A. Synthesis of prostaglandin I₂ (prostacyclin) by cultured human and bovine endothelial cells. Proc Natl Acad Sci USA 1977; 74: 3922-6.
• 129 Weksler B B, Knapp J, Jaffe E A. Prostacyclin (PGI₂) synthesized by cultured endothelial cells modulates polymorphonuclear leukocyte function. Blood 1977; 50: 287.
• 130 Weksler B B, Ley C W, Jaffe E A. Stimulation of endothelial cell prostacyclin production by thrombin, trypsin, and the ionophore A 23187. J Clin Invest 1978; 62: 923-30.
• 131 Weksler B B. Prostacyclin. Prog Hemost Thromb 1982; 06: 113-38.
• 132 Wetmore R, Gurewich V. The role of fibrin monomer and in vivo thrombininduced anticoagulant in experimental venous thrombosis. Scand J Haematol 1974; 12: 204-12.
• 133 Williams R S, Logue E E, Lewis J L, Barton T, Stead N, Wallace A G, Pizzo S V. Physical conditioning augments the fibrinolytic response to venous occlusion in healthy adults. N Engl J Med 1980; 302: 987-91.
• 134 Wiman B, Mellbring G, Ranby M. Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin Chim Acta 1983; 127: 279-88.
• 135 Wiman B, Wallen P. The specific interaction between plasminogen and fibrin. A physiological role of the lysine binding site in plasminogen. Thromb Res 1977; 10: 213-22.
• 136 Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 1978; 84: 573-8.
• 137 Wiman B, Ljungberg B, Chmielewska J, Urden G, Blombäck M, Johnson H. The role of the fibrinolytic system in deep vein thrombosis. J Lab Clin Med 1985; 105: 265-70.